Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1671 1681 1682 1683
This examiner grants 43% of resolved cases
Katherine D Salmon has resolved 797 cases in Tech Center 1600. The allowance rate is 42.8 percent. This figure reflects a challenging prosecution environment within Art Unit 1634. Practitioners should be prepared for a rigorous examination process where the 42.8 percent allowance rate indicates that grants are more difficult to obtain.
The interview lift is 37.9 percent. This high lift indicates that direct communication with the examiner is one of the most effective ways to improve the chances of allowance. A 37.9 percent increase in the probability of success following an interview is a strong indicator that personal engagement can significantly overcome initial rejections.
The median days to allowance is 1471. This is a lengthy pendency, suggesting that successful prosecution requires persistence. The combination of a low 42.8 percent allowance rate and high interview lift suggests that strategic interviews are essential for navigating the 1471 day timeline and achieving a successful outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16309271 | COMPOSITIONS AND METHODS FOR DETECTION OF NUCLEIC ACID MUTATIONS | Final Rejection | Natera, Inc. |
| 18023598 | PREDICTION OF A RESPONSE OF A PROSTATE CANCER SUBJECT TO THERAPY OR PERSONALIZATION OF THERAPY OF A PROSTATE CANCER SUBJECT | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 18540517 | BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION | Final Rejection | Wisconsin Alumni Research Foundation |
| 18787942 | METHODS AND COMPOSITIONS FOR METHYLATION AND CHEMICALLY MODIFYING ASSISTED TAILORABLE ENDS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18261091 | LAYERED ANALYSIS OF METHYLATED BIOMARKERS FOR USE IN CANCER DIAGNOSIS AND PROGNOSIS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18261874 | METHODS FOR DETECTING utDNA | Final Rejection | Washington University |
| 18575255 | SINGLE-CELL PROFILING OF RNA TRANSLATION STATUS | Non-Final OA | Massachusetts Institute of Technology |
| 18278800 | ORAL CANCER DETECTION KIT, USE OF REAGENT, REAGENT, ORAL CANCER DETECTION DEVICE, INFORMATION ACQUISITION METHOD, AND PROGRAM | Non-Final OA | Tohoku University |
| 18152346 | Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18563676 | LINKED AMPLIFICATION TETHERED WITH EXPONENTIAL RADIANCE | Final Rejection | CALIFORNIA INSTITUTE OF TECHNOLOGY |
| 18595057 | DIAGNOSIS OF ACUTE AND CHRONIC LUNG DISEASES BY QUANTIFYING SPINK1 LEVEL | Non-Final OA | Northwestern University |
| 18548175 | CELL-FREE BIOSENSORS WITH DNA STRAND DISPLACEMENT CIRCUITS | Non-Final OA | Northwestern University |
| 18035888 | High Throughput Microfluidics for Analysis of Immune Cell Activation | Non-Final OA | The General Hospital Corporation |
| 18427553 | Systems for Processing a Cellular Sample, Multi-Microwell Array-Flowcell Cartridges for Use Therein, and Methods of Use Thereof | Final Rejection | Becton, Dickinson and Company |
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | Final Rejection | Board of Regents, The University of Texas System |
| 18050855 | METHODS AND SYSTEMS FOR IMPROVING PATIENT MONITORING AFTER SURGERY | Non-Final OA | GUARDANT HEALTH, INC. |
| 18269171 | SELECTIVE LYSIS OF HUMAN BLOOD CELLS | Final Rejection | Roche Molecular Systems, Inc. |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | Final Rejection | William Marsh Rice University |
| 17984444 | SURFACE-ENHANCED RAMAN SCATTERING (SERS) BIOSENSOR FOR DIAGNOSING PROSTATE CANCER WITH HIGH SENSITIVITY | Non-Final OA | Korea University Research and Business Foundation |
| 18575242 | ANALOG CIRCUIT TO COMPENSATE BIAS OFFSET IN AMPLIFIER ARRAY | Non-Final OA | ILLUMINA, INC. |
| 18568366 | DETECTING METHYLCYTOSINE USING A MODIFIED BASE OPPOSITE TO THE METHYLCYTOSINE | Final Rejection | ILLUMINA, INC. |
| 18323031 | DETECTING PROSTATE CANCER | Non-Final OA | Exact Sciences Corporation |
| 17587963 | DETECTING THE PRESENCE OR ABSENCE OF MULTIPLE TYPES OF CANCER | Non-Final OA | Exact Sciences Corporation |
| 18011145 | METHYLATED DNA FRAGMENT ENRICHMENT, METHODS, COMPOSITIONS AND KITS | Final Rejection | GRAIL, INC |
| 18015989 | Methods for Classifying Cancer | Final Rejection | Kingston Health Sciences Centre |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy